Rosetta Genomics

Rosetta Genomics EBIT

The EBIT of Rosetta Genomics (ROSGQ) as of Oct 16, 2026 is -15.66 M USD. In the previous year, EBIT was -15.88 M USD — a change of -1.34% (higher).

EBIT

-15.66 MUSD

YoY

-1.34%

Last updated:

In 2016, Rosetta Genomics's EBIT was -15.66 M USD, a -1.34% increase from the -15.88 M USD EBIT recorded in the previous year.

The Rosetta Genomics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2011
-8.78 M USD
Jan 1, 2012
-8.27 M USD
Jan 1, 2013
-13.35 M USD
Jan 1, 2014
-14.25 M USD
Jan 1, 2015
-15.88 M USD
Jan 1, 2016
-15.66 M USD
Jan 1, 2017 (e)
-14.98 M USD
Jan 1, 2018 (e)
-15.09 M USD
The Rosetta Genomics EBIT history
YEAREBITYoY
est-15.09 MUSD+0.70%
est-14.98 MUSD-4.36%
-15.66 MUSD-1.34%
-15.88 MUSD+11.39%
-14.25 MUSD+6.78%
-13.35 MUSD+61.45%
-8.27 MUSD-5.81%
-8.78 MUSD-41.91%
-15.11 MUSD+2.09%
-14.80 MUSD+5.41%
-14.04 MUSD+27.17%
-11.04 MUSD+35.46%
-8.15 MUSD+57.34%
-5.18 MUSD+73.83%
-2.98 MUSD+26.81%
-2.35 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rosetta Genomics Revenue

Rosetta Genomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2011
103,000.00 USD
-8.78 M USD
-8.83 M USD
Jan 1, 2012
201,000.00 USD
-8.27 M USD
-10.46 M USD
Jan 1, 2013
405,000.00 USD
-13.35 M USD
-12.90 M USD
Jan 1, 2014
1.33 M USD
-14.25 M USD
-14.53 M USD
Jan 1, 2015
8.27 M USD
-15.88 M USD
-17.35 M USD
Jan 1, 2016
9.23 M USD
-15.66 M USD
-16.23 M USD
Jan 1, 2017 (e)
20.13 M USD
-14.98 M USD
-19.43 M USD
Jan 1, 2018 (e)
39.46 M USD
-15.09 M USD
-25.79 M USD

Rosetta Genomics Margins

Rosetta Genomics stock margins

The Rosetta Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rosetta Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rosetta Genomics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2011
-214.56 %
-8,521.36 %
-8,572.82 %
Jan 1, 2012
-28.36 %
-4,112.94 %
-5,202.49 %
Jan 1, 2013
-75.06 %
-3,295.56 %
-3,184.44 %
Jan 1, 2014
1.28 %
-1,074.00 %
-1,094.65 %
Jan 1, 2015
24.14 %
-192.02 %
-209.78 %
Jan 1, 2016
19.44 %
-169.63 %
-175.80 %
Jan 1, 2017 (e)
19.44 %
-74.41 %
-96.51 %
Jan 1, 2018 (e)
19.44 %
-38.23 %
-65.34 %

Rosetta Genomics Stock analysis

What does Rosetta Genomics do? Rosetta Genomics Ltd is a company specializing in personalized medicine, focused on the development and commercialization of diagnostic tests based on RNA interference and NGS technologies for cancer diseases. The company was founded in 2000 and has its headquarters in Israel, with offices in the USA and Europe. The history of Rosetta Genomics began with the development of MicroRNA (miRNA), RNA molecules that act as regulators of gene expression in cells. The company developed a technology that allows for the identification of specific miRNAs that are characteristic of different types of cancers. As a result, Rosetta Genomics started developing a series of diagnostic tests based on these miRNAs to enable personalized therapy for cancer patients. Rosetta Genomics' business model is based on the commercialization of diagnostic tests for various cancer types. These tests can be requested by doctors and other medical professionals to determine the best treatment for patients. The company works closely with clinicians and researchers to continually improve its tests and stay up to date with the latest technology. The company operates in two main divisions: RosettaGX and RosettaWGX. RosettaGX offers diagnostic tests for various cancer types, including lung cancer, thyroid cancer, and colorectal cancer. These tests utilize Rosetta Genomics' proprietary RNA interference technology to identify specific miRNAs indicative of a particular type of cancer. On the other hand, RosettaWGX offers NGS services that allow researchers and pharmaceutical companies to collect and analyze DNA sequencing data to gain insights into the genetics of cancer. Some of the products offered by Rosetta Genomics include the miRview® Lung Test, miRview® mets2 Test, and miRview® Thyroid Test. The miRview® Lung Test identifies specific miRNAs characteristic of various types of lung tumors to enable an accurate diagnosis. The miRview® mets2 Test can determine the origin of cancer cells that have spread from the primary site, enabling targeted treatment. The miRview® Thyroid Test enables an accurate diagnosis of thyroid cancer and can determine the likelihood of a more aggressive form of the disease. Overall, Rosetta Genomics has developed a wide range of diagnostic tests and services based on a unique technology platform to enable personalized medicine for cancer patients. The company collaborates closely with doctors, researchers, and pharmaceutical companies to continually improve its tests and stay at the forefront of technology. With its innovative products and services, Rosetta Genomics is an important player in the field of personalized medicine and contributes to improving treatment outcomes for cancer patients. Rosetta Genomics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Rosetta Genomics's EBIT

Rosetta Genomics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Rosetta Genomics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Rosetta Genomics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Rosetta Genomics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Rosetta Genomics stock

EBIT of Rosetta Genomics is -15.66 M USD in 2016.

EBIT of Rosetta Genomics changed from -15.88 M USD to -15.66 M USD, representing a -1.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Rosetta Genomics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Rosetta Genomics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Rosetta Genomics

All Key Metrics — Rosetta Genomics